- Complementary peptide-mapping methods increased coverage of the active botulinum neurotoxin primary sequence from approximately 93% to 98%, with 100% amino acid identity across all regions analyzed 

- Preliminary analysis demonstrates preservation of the critical disulfide bond architecture required for toxin activation

- Primary amino acid sequence and disulfide connectivity are foundational to establishing molecular similarity between ABP-450 and BOTOX®

- FDA feedback from planned Biosimilar Biological Product Development (BPD) Type 2b interaction expected to help inform the next phase of ABP-450 development

ALISO VIEJO, Calif., Aug. 19, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced final, expanded primary structure results and preliminary disulfide bond characterization data that provide complementary evidence supporting the molecular similarity of ABP-450 to BOTOX®. The expanded primary structure analysis achieved 98% sequence coverage of the active botulinum neurotoxin and demonstrated 100% amino acid identity across every region analyzed. Preliminary disulfide characterization identified the same C430-C454 bond connecting the light and heavy chains in both products across all tested lots.